{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:19:41Z","timestamp":1789067981782,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lifestyle-Related Disease of the Public Health Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Aggressive lipid lowering by high-dose statin treatment has been established for the secondary prevention of coronary artery disease (CAD). Regarding the low-density lipoprotein cholesterol (LDL-C) level, however, the \u201cThe lower is the better\u201d concept has been controversial to date. We hypothesized that there is an optimal LDL-C level, i.e., a \u201cthreshold\u201d value, below which the incidence of cardiovascular events is no longer reduced. We undertook a subanalysis of the REAL-CAD study to explore whether such an optimal target LDL-C level exists by a novel analysis procedure to verify the existence of a monotonic relationship.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>For a total of 11,105 patients with CAD enrolled in the REAL-CAD study, the LDL-C level at 6 months after randomization and 5-year cardiovascular outcomes were assessed. We set the \u201cthreshold\u201d value of the LDL-C level under which the hazards were assumed to be constant, by including an artificial covariate max (0, LDL-C \u2212 threshold) in the Cox model. The analysis was repeated with different LDL-C thresholds (every 10 mg\/dl from 40 to 100 mg\/dl) and the model fit was assessed by log-likelihood.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For primary outcomes such as the composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and unstable angina requiring emergency hospitalization, the model fit assessed by log-likelihood was best when a threshold LDL-C value of 70 mg\/dl was assumed. And in the model with a threshold LDL-C \u2265 70 mg\/dl, the hazard ratio was 1.07 (95% confidence interval 1.01\u20131.13) as the LDL-C increased by 10 mg\/dl. Therefore, the risk of cardiovascular events decreased monotonically until the LDL-C level was lowered to 70 mg\/dl, but when the level was further reduced, the risk was independent of LDL-C.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our analysis model suggests that a \u201cthreshold\u201d value of LDL-C might exist for the secondary prevention of cardiovascular events in Japanese patients with CAD, and this threshold might be 70 mg\/dl for primary composite outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>. Unique identifier: NCT01042730.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-022-02633-5","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T01:03:10Z","timestamp":1668387790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events"],"prefix":"10.1186","volume":"20","author":[{"given":"Masashi","family":"Sakuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Iimuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Daida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Nishihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masunori","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryozo","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"2633_CR1","doi-asserted-by":"crossref","unstructured":"Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet. 1994;344(8934):1383\u20139.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"issue":"14","key":"2633_CR2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 1996;335(14):1001\u20139.","journal-title":"N Engl J Med"},{"key":"2633_CR3","doi-asserted-by":"crossref","unstructured":"Influence of pravastatin and plasma lipids on clinical events in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 1998;97(15):1440\u20135.","DOI":"10.1161\/01.CIR.97.15.1440"},{"key":"2633_CR4","doi-asserted-by":"crossref","unstructured":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349\u201357.","DOI":"10.1056\/NEJM199811053391902"},{"issue":"9326","key":"2633_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360(9326):7\u201322.","journal-title":"Lancet."},{"issue":"9364","key":"2633_CR6","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahl\u00f6f B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial--lipid lowering arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet. 2003;361(9364):1149\u201358.","journal-title":"Lancet."},{"issue":"9435","key":"2633_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicenter randomized placebo-controlled trial. Lancet. 2004;364(9435):685\u201396.","journal-title":"Lancet."},{"issue":"9542","key":"2633_CR8","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","volume":"368","author":"H Nakamura","year":"2006","unstructured":"Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomized controlled trial. Lancet. 2006;368(9542):1155\u201363.","journal-title":"Lancet."},{"issue":"11","key":"2633_CR9","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","volume":"292","author":"JA de Lemos","year":"2004","unstructured":"de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the a to Z trial. JAMA. 2004;292(11):1307\u201316.","journal-title":"JAMA."},{"issue":"14","key":"2633_CR10","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"19","key":"2633_CR11","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","volume":"294","author":"TR Pedersen","year":"2005","unstructured":"Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437\u201345.","journal-title":"JAMA."},{"issue":"15","key":"2633_CR12","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504.","journal-title":"N Engl J Med"},{"issue":"3","key":"2633_CR13","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","volume":"48","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2633_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT Jr, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227\u201339.","journal-title":"Circulation."},{"issue":"16","key":"2633_CR15","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","volume":"57","author":"J Hsia","year":"2011","unstructured":"Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg\/dl with rosuvastatin. The JUPITER trial (Justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol. 2011;57(16):1666\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"2633_CR16","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"18","key":"2633_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"2633_CR18","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"2","key":"2633_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1620\/tjem.255.123","volume":"255","author":"Y Yonezawa","year":"2021","unstructured":"Yonezawa Y, Sakuma M, Horinaka S, Abe S, Shibazaki I, Toyoda S, et al. Repeated in-stent restenosis despite aggressive lipid lowering by the PCSK-9 inhibitor treatment: a case report. Tohoku J Exp Med. 2021;255(2):123\u20136.","journal-title":"Tohoku J Exp Med"},{"issue":"19","key":"2633_CR20","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.117.032615","volume":"137","author":"I Taguchi","year":"2018","unstructured":"Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation. 2018;137(19):1997\u20132009.","journal-title":"Circulation."},{"issue":"6","key":"2633_CR21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/EDE.0000000000000363","volume":"26","author":"T Shinozaki","year":"2015","unstructured":"Shinozaki T, Matsuyama Y. Doubly robust estimation of standardized risk difference and ratio in the exposed population. Epidemiology. 2015;26(6):873\u20137.","journal-title":"Epidemiology."},{"issue":"9","key":"2633_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.5551\/jat.GL2017","volume":"25","author":"M Kinoshita","year":"2018","unstructured":"Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018;25(9):846\u201384.","journal-title":"J Atheroscler Thromb"},{"issue":"14","key":"2633_CR23","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","volume":"39","author":"KC Koskinas","year":"2018","unstructured":"Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Raber L, Mach F, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39(14):1172\u201380.","journal-title":"Eur Heart J"},{"issue":"11","key":"2633_CR24","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","volume":"43","author":"JH O'Keefe Jr","year":"2004","unstructured":"O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43(11):2142\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"9753","key":"2633_CR25","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet."},{"issue":"1","key":"2633_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"24","key":"2633_CR27","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2633_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1001\/jamainternmed.2022.0134","volume":"182","author":"P Byrne","year":"2022","unstructured":"Byrne P, Demasi M, Jones M, Smith SM, O\u2019Brien KK, DuBroff R. Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment: a systematic review and meta-analysis. JAMA Intern Med. 2022;182(5):474\u201381.","journal-title":"JAMA Intern Med"},{"key":"2633_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89\u2013118.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"2633_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229\u201343.","journal-title":"Circ Res"},{"issue":"13","key":"2633_CR31","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1161\/01.CIR.0000091404.09558.AF","volume":"108","author":"S Kinlay","year":"2003","unstructured":"Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108(13):1560\u20136.","journal-title":"Circulation."},{"issue":"21","key":"2633_CR32","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207.","journal-title":"N Engl J Med"},{"issue":"12","key":"2633_CR33","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02633-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02633-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02633-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T01:06:32Z","timestamp":1668387992000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02633-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2633"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02633-5","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"assertion":[{"value":"21 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Public Health Research Foundation ethics review committee (CSP-LD 09) and by the ethics committees at all participating centers. All the study patients provided written informed consent. All clinical investigations were conducted according to the Declaration of Helsinki. The research has been registered at  (. Unique identifier: NCT01042730).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yoshihisa Nakagawa, Hiroshi Iwata, Hiroyuki Daida, Ichiro Sakuma, and Ryozo Nagai received honoraria from Kowa Pharmaceutical Co, Ltd, Nagoya, Japan, the pharmaceutical company that developed pitavastatin. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"441"}}